The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DSKYF | -19.59% | +7.54% | +1.47% | +274% |
| S&P | +18.37% | +110.18% | +16.02% | +437% |
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.28B | 17.3% |
| Gross Profit | $2.65B | 20.8% |
| Gross Margin | 80.54% | 2.3% |
| Market Cap | $40.76B | -38.1% |
| Market Cap / Employee | $2.06M | 0.0% |
| Employees | 19.8K | 5.5% |
| Net Income | $591.73M | 8.0% |
| EBITDA | $787.27M | 49.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.98B | -20.6% |
| Accounts Receivable | $4.24B | 25.1% |
| Inventory | 3.9K | 41.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $698.10M | 10.9% |
| Short Term Debt | $695.06M | 27921.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 8.74% | 1.0% |
| Return On Invested Capital | 8.96% | 1.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$451.84M | 46.3% |
| Operating Free Cash Flow | -$253.07M | 64.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 37.95 | 32.65 | 22.93 | 22.05 | -48.90% |
| Price to Book | 5.66 | 4.45 | 4.01 | 3.78 | -35.89% |
| Price to Sales | 5.35 | 4.41 | 3.57 | 3.37 | -42.17% |
| Price to Tangible Book Value | 6.80 | 5.50 | 5.13 | 4.80 | -31.98% |
| Price to Free Cash Flow TTM | 17.32 | 20.26 | 26.29 | 23.45 | - |
| Enterprise Value to EBITDA | 78.97 | 93.89 | 61.19 | 51.71 | -55.74% |
| Free Cash Flow Yield | 5.8% | 4.9% | 3.8% | 4.3% | - |
| Return on Equity | 15.1% | 15.0% | 17.6% | 18.3% | 27.82% |
| Total Debt | $709.75M | $645.39M | $1.04B | $1.39B | 120.54% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
